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Although it is known that bisphosphonates prevent medial
vascular calcification in vivo, their mechanism of action
remains unknown and, in particular, whether they act directly
on the blood vessels or indirectly through inhibition of bone
resorption. To determine this, we studied the effects of two
bisphosphonates on calcification of rat aortas in vitro and on
in vivo aortic calcification and bone metabolism in rats with
renal failure. We produced vascular calcification in rats with
adenine-induced renal failure fed a high-phosphate diet.
Daily treatment with either etidronate or pamidronate
prevented aortic calcification, with the latter being 100-fold
more potent. Both aortic calcification and bone formation
were reduced in parallel; however, bone resorption was not
significantly affected. In all uremic rats, aortic calcium content
correlated with bone formation but not with bone
resorption. Bisphosphonates also inhibited calcification of rat
aortas in culture and arrested further calcification of
precalcified vessels but did not reverse their calcification.
Expression of osteogenic factors or calcification inhibitors
was not altered by etidronate in vitro. Hence, these studies
show that bisphosphonates can directly inhibit uremic
vascular calcification independent of bone resorption. The
correlation between inhibition of aortic calcification and
bone mineralization is consistent with a common mechanism
such as the prevention of hydroxyapatite formation and
suggests that bisphosphonates may not be able to prevent
vascular calcification without inhibiting bone formation in
uremic rats.
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Calcification of the medial layer of arteries is common in
renal failure and is thought to contribute to the increased
incidence of cardiovascular disease in this population. Recent
studies have shown that medial calcification is a far more
complex process than simple precipitation of calcium
phosphate. It is clear that several endogenous inhibitors of
hydroxyapatite formation are responsible for preventing
vascular calcification under normal conditions1 and must
be deficient in pathologic calcification. Vascular calcification
is also associated with osteogenic changes in smooth muscle2
and with altered bone metabolism,3 suggesting additional
pathophysiologic mechanisms. We have shown that pyropho-
sphate (PPi), a potent inhibitor of hydroyapatite forma-
tion,4–6 is produced by smooth muscle in quantities sufficient
to prevent medial calcification in vitro.7 Plasma PPi levels are
reduced in hemodialysis patients8 and PPi levels in the
vascular wall may be reduced in uremia by virtue of increased
alkaline phosphatase activity.9 Humans and mice with low
levels of PPi due to the absence of PC-1, a membrane-bound
ecto-nucleotide pyrophosphatase/phosphodiesterase that
produces PPi,10–12, develop severe, fatal arterial calcification,
indicating that PPi deficiency could contribute to vascular
calcification in renal failure.
Systemic administration of PPi to vitamin D-toxic rats
prevents vascular calcification13 but this approach is limited
by the susceptibility of PPi to hydrolysis. Bisphosphonates are
nonhydrolyzable analogs of pyrophosphate that were origin-
ally developed to treat ectopic calcification. Although early
compounds were successful at preventing vascular calcifica-
tion in rats,6,14,15, inhibition of bone formation limited this
approach in humans.15 It was assumed that the prevention
of vascular calcification as well as the inhibition of
bone formation were due to a physicochemical effect of
the bisphosphonates related to their PPi-like structure.
Subsequent chemical modifications imparted an additional
biological action that yielded newer bisphosphonates that are
far more potent at inhibiting bone resorption than bone
formation. Recent studies with these compounds have shown
that medial vascular calcification produced by vitamin D,
warfarin, or renal failure in rats can be prevented at relative
potencies that match those for inhibition of bone resorption
rather than bone formation.16–18
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Based on these results, it has been assumed that the
prevention of vascular calcification is related to the
antiresorptive activity of bisphosphonates in bone, thus
supporting the putative link between bone resorption and
vascular calcification. However, effects on bone were not
examined in these studies and bisphosphonates can inhibit
calcium deposition in vascular smooth muscle cells in
culture.19 Thus, the possibility that bisphosphonates directly
inhibit vascular calcification in renal failure independent of
effects on bone cannot be excluded. Whether calcification can
be prevented without reducing bone mineralization is also
unknown. Using two bisphosphonates with different relative
potencies for inhibition of bone resorption and formation,
we compared vascular calcification and bone metabolism in
vivo in rats with renal failure. An in vitro model of vascular
calcification in cultured rat aortas was used to examine direct
effects of bisphosphonates independent of bone.
RESULTS
Rats were fed with adenine for 28 days together with a high-
phosphate diet to induce renal failure and vascular calcifica-
tion. One rat treated with the highest dose of etidronate was
killed on day 22 due to distress. One rat receiving the lowest
dose of pamidronate died on day 27 and was not included in
the results. The resulting plasma concentrations of urea,
calcium, and phosphate in rats receiving etidronate, pami-
dronate, or vehicle are shown in Figure 1. Plasma urea
increased 2.5- to 4-fold in vehicle-treated, adenine-fed rats
compared with pair-fed control rats. Pamidronate did not
alter the plasma urea concentration at any dose but it was
significantly increased at the two highest etidronate doses.
Plasma urea did not differ between rats treated with
etidronate or pamidronate at similar doses. The plasma
phosphate concentration was substantially elevated in uremic
rats and was slightly decreased and substantially increased at
the highest and lowest doses of etidronate respectively.
Plasma phosphate was not significantly altered by pamidro-
nate although it was lower than in etidronate-treated rats.
Plasma calcium was not altered by uremia or pamidronate
but was significantly reduced at the highest etidronate dose.
At similar doses, the plasma calcium concentration was lower
in the pamidronate-treated rats. Plasma parathyroid hor-
mone concentration was markedly elevated in uremic rats but
not altered by bisphosphonates.
Extensive aortic calcification developed in half of the
uremic rats treated with vehicle alone. As shown in Figure 2,
both bisphosphonates reduced aortic calcification. Complete
inhibition was obtained at 0.08 mmol/kg per day of
pamidronate and at 8mmol/kg per day of etidronate. Samples
of bone were examined from the same rats. Bone volume,
osteoid volume, and cortical thickness were not altered in
uremic rats and were unaffected by bisphosphonate (Table 1).
Parameters of bone resorption are shown in Figure 3. Erosion
depth and osteoclast number both increased (but not
significantly) in adenine-fed rats compared with pair-fed
nonuremic rats and tended to be higher in etidronate-treated
rats than in pamidronate-treated rats. Although there was a
decreasing trend with increasing doses of bisphosphonate,
none of the changes were significant. Parameters of bone
formation are presented in Figure 4. Both bone formation
rate (2.7-fold; P¼ 0.0009) and osteoblast number (20-fold;
P¼ 0.0013) were increased in the adenine-fed rats. Bispho-
sphonates completely eliminated bone formation, with
pamidronate being at least 10-fold more potent, but
osteoblast number was reduced only at the highest dose of
etidronate. Mineralizing surface (1.5-fold; P¼ 0.05) was also
increased in the adenine-fed rats and substantially reduced
with bisphosphonates, again with pamidronate being at least
10-fold more potent (Table 1).
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Figure 1 | Plasma chemistries in bisphosphonate-treated rats.
Open symbols, etidronate-treated rats; solid symbols,
pamidronate-treated rats; shaded symbols: nonuremic rats. There
are separate untreated uremic controls for pamidronate and
etidronate-treated rats. *Po0.05, **Po0.02, ***Po0.005 versus
untreated adenine-fed rats; #Po0.05, ##Po0.02, ###Po0.01 versus
etidronate-treated rats.
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Parameters of bone formation and resorption were
compared with aortic calcium content by linear regression
in the entire cohort of adenine-fed rats (Figure 5). Owing to
the large range of values for aortic calcium, regression was
performed using the logarithm of calcium content to
minimize skewing of the data. Of all the parameters of bone
formation examined, bone formation rate correlated best
with aortic calcium content (Figure 5, top). The correlation
between aortic calcium content and bone formation rate
was 0.41 (0.48 when the outlying value was omitted). Aortic
calcium also correlated significantly with osteoblast surface
(r¼ 0.31), osteoblast number (r¼ 0.35), and mineralizing
surface (r¼ 0.34). In contrast, there was no significant
correlation between aortic calcium content and osteoclast
number (Figure 5, bottom). Correlation with other para-
meters of bone resorption was even poorer (not shown).
To determine whether bisphosphonates can affect vascular
calcification directly, independent of effects on bone, studies
were repeated in normal rat aortas in culture. Culture of rat
aortas with alkaline phosphatase results in medial calcifica-
tion after 9 days by virtue of removing pyrophosphate.7
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Figure 2 | Effect of bisphosphonates on aortic calcification in
renal failure. Solid symbols, pamidronate-treated rats; **Po0.05
versus untreated uremic rats by Mann–Whitney U-test. Open
symbols, etidronate-treated rats; *Po0.02 versus untreated
uremic rats by Mann–Whitney U-test.
Table 1 | Bone parameters in control and bisphosphonate-
treated uremic rats
Treatment
Dose
lmol/kg
per day
Bone
volume
%
Cortical
thickness
lm
Osteoid
thickness
lm
Mineralization
surface
%
No adenine 12.5±1.6 494±34 3.64±0.50 13.0±1.4
Adenine+ 0 14.5±2.1 594±31 3.82±0.58 21.4±3.8
etidronate 0.8 10.9±1.1 637±28 5.04±1.0 21.7±2.6
8 14.6±1.1 649±20 12.2±3.0** 9.2±1.5**
80 15.5±1.3 621±27 6.43±1.5 3.3±0.9***
Adenine+ 0 13.8±2.3 478±31 4.36±0.45 19.7±2.8
pamidronate 0.08 10.4±0.6 540±29 6.23±2.2 10.3±1.6**
0.8 10.3±1.7 525±23 3.27±0.61 9.6±2.1*
8 13.9±2.1 466±18 5.75±1.7 1.4±0.2***
*Po0.05, **Po0.02, ***Po0.005 vs untreated uremic.
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Figure 3 | Parameters of bone resorption in bisphosphonate-
treated rats. Top: erosion depth. Bottom: osteoclast number.
Solid symbols, pamidronate-treated; open symbols, etidronate-
treated rats; triangles: control, nonuremic rats. There are separate
untreated uremic controls for pamidronate and etidronate-treated
rats. #Po0.02, ##Po0.005 versus etidronate-treated rats.
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Figure 4 | Parameters of bone formation in bisphosphonate-
treated rats. Top: Bone formation rate per bone surface. Bottom:
Number of osteoblasts per mm bone perimeter. There are
separate untreated uremic controls for pamidronate and
etidronate-treated rats. *Po0.01, **Po0.005, ***Po0.002 versus,
control uremic rats; #Po0.01, ##Po0.005 versus etidronate-treated
rats.
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Warfarin, which increases calcification in vitro by reducing
levels of matrix Gla protein (KA Lomashvili and WC O’Neill,
unpublished data), was added to maximize calcification and
provide a more precise comparison between the two agents.
As shown in Figure 6a, calcification was prevented by
increasing concentrations of etidronate or pamidronate, with
complete inhibition at 0.1 and 1mM, respectively. Inhibition
of calcification was also observed in the absence of MGP (not
shown). Medial calcification of aortas can also be produced
in culture without alkaline phosphatase when the vessels are
injured prior to culture by rubbing with a cotton swab. As
shown in Figure 6b, substantially greater concentrations of
pamidronate were required to inhibit calcification in injured
aortas than in uninjured aortas cultured with alkaline
phosphatase. A similar decrease in potency in injured aortas
was observed with etidronate (not shown).
As bisphosphonates have been reported to inhibit alkaline
phosphatase,20 reduction of PPi hydrolysis by alkaline
phosphatase could be a potential mechanism for the
prevention of calcification by bisphosphonates. However,
hydrolysis of PPi by rat aortas was not altered by 10 mM
pamidronate (data not shown), a concentration that
completely prevented calcification in cultured aortas. Studies
were also performed to determine whether bisphosphonates
alter the expression of calcification inhibitors or osteogenic
factors in vascular smooth muscle (Table 2). Messenger RNA
was measured by quantitative polymerase chain reaction and
normalized to 18S RNA. Substantial quantities of mRNA for
both matrix Gla protein and osteopontin were detected after
3 days in normal medium and even higher levels were
observed after 9 days in high-phosphate medium with
alkaline phosphatase (calcifying conditions). The levels in
aortas cultured for 9 days in normal medium were similar to
5
4
3
2
1
No. of osteoclasts/ mm bone perimeter
Bone formation rate (mm3/cm2 per year)
Lo
g 
ao
rti
c 
ca
lci
um
 c
on
te
nt
(nm
ol/
mg
)
Lo
g 
ao
rti
c 
ca
lci
um
 c
on
te
nt
(nm
ol/
mg
)
5
4
3
2
1
5 6 74320 1
0 10 20 30 40 50 60 70
r = 0.41; P<0.005
r = 0.16; P >0.2 
Figure 5 | Correlation between aortic calcium content and
bone histomorphometry in uremic rats treated with or
without bisphosphonates. Top: bone formation rate per bone
surface; bottom: number of osteoclasts per bone perimeter. Open
symbols: rats treated with etidronate or pamidronate. Solid
symbols: rats treated with vehicle alone. Lines are linear
regressions.
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Figure 6 | Effect of bisphosphonates on calcification of rat
aortas in culture. Top: Aortas were incubated in DMEM
containing 3.8 mM phosphate, 3.75 U/ml of alkaline phosphatase,
25mM warfarin, and the indicated concentrations of
bisphosphonate for 9 days. Results are the means±s.e. of seven
aortic rings. Bottom: Injured and uninjured aortas were incubated
in DMEM with 3.8 mM phosphate, with or without 3.75 U/ml of
alkaline phosphatase, and the indicated concentrations of
pamidronate for 9 days. Results are the means±s.e. of at least
three aortic rings.
Table 2 | Abundance of mRNA in aortas cultured with or
without 1 lM etidronate
3 days (low phosphate
without AP)
9 days (high phosphate
with AP)
Etidronate Control P Etidronate Control P
MGP 776±66 888±76 NS 1760±729 2630±1110 NS
OPN 194±26 128±21 NS 1420±494 1770±634 NS
Runx2 1.7±0.4 1.6±0.5 NS 17±3 68±40 NS
Osterix 0.07±0.03 0.038±0.024 NS o0.01 o0.01 NS
AP, alkaline phosphatase; MGP, matrix gla protein; OPN, osteopontin.
Values are copies per 105 copies of 18S RNA.
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those after 3 days (not shown). In contrast, expression of the
transcription factor runx2 (cbfa-1) was very low after 3 days
in normal medium, consistent with levels in fresh aorta (not
shown). The slightly higher levels in aortas cultured for 9
days under calcifying conditions were also observed in aortas
cultured for 9 days in normal medium (not shown).
Expression of the bone-specific transcription factor osterix
was extremely low. Etidronate at 1mM did not alter the
content of any of the mRNAs at either 3 days in normal
medium or 9 days under calcifying conditions.
Additional studies were performed to determine whether
bisphosphonates could also arrest or reverse existing
calcification. To examine the effect on progression of
calcification, aortas were cultured with alkaline phosphatase
for 9 days in the absence of etidronate and then cultured an
additional 6 days with alkaline phosphatase and varying
concentrations of etidronate (Figure 7). Culture for an
additional 6 days without etidronate resulted in a further
195% increase in calcification (Po0.02). This increase was
prevented by etidronate but at higher concentrations
(approximately 10-fold) than required to prevent de novo
calcification. There was no further reduction at etidronate
concentrations above 0.25 mM. Although calcification at 15
days was less than the calcification at 9 days at maximum
concentrations of etidronate, suggesting reversal, the differ-
ence was not significant. To examine reversibility of
calcification directly, release of 45Ca was measured in
precalcified aortas. The results are shown in Figure 8,
with the fraction of 45Ca remaining fitting a biexponential
decline (r40.99). Approximately 14% of the calcium
exhibited a half-life of 16.0±0.8 h while the bulk of the
calcium had a much longer half-life of 2920±351 h. Neither
half-life was altered by 30 mM etidronate (14.0±0.8 h and
2980±421 h).
DISCUSSION
Both etidronate and pamidronate prevented aortic calcifica-
tion in uremic rats, confirming previous studies of bispho-
sphonates in the same model18 and other models6,16,17 of
vascular calcification. Inhibition of calcification cannot be
explained by changes in the circulating phosphate or calcium
levels. Etidronate completely prevented calcification at
8 mmol/kg per day despite plasma calcium and phosphate
levels that were almost identical to levels in untreated rats.
Although the plasma calcium concentration was decreased at
the highest dose of etidronate, any effect on calcification
would have been offset by the concurrent increase in
phosphate concentration. Plasma calcium and phosphate
levels were reduced at the two highest doses of pamidronate
compared with untreated rats, but the differences were not
significant. Furthermore, pamidronate completely suppressed
calcification at the lowest dose despite no change in plasma
calcium or phosphate concentration. Although a decrease in
plasma calcium might have been expected based on clinical
experience, the bisphosphonates had little effect on bone
resorption and the inhibition of bone formation would have
countered any decrease in circulating calcium levels. Bispho-
sphonates also failed to lower calcium levels in a previous
study in uremic rats.21 The higher phosphate and lower
calcium levels at the highest etidronate dose probably reflect
worse renal failure as indicated by the higher urea level. This
is consistent with reports of renal failure with high doses of
bisphosphonates.22
The fact that the potency of different bisphosphonates in
previous studies of vascular calcification paralleled their
reported antiresorptive potencies in vivo has been taken as
evidence that medial vascular calcification is linked to bone
resorption. However, no bone histology has been presented
to support this hypothesis. The relative potencies of
etidronate and pamidronate in the current study also
paralleled the reported potencies for inhibition of bone
resorption, but bone histology did not support a link
between inhibition of vascular calcification and inhibition
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washout as described in ‘Materials and Methods’. Results are
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of bone resorption. The effect of bisphosphonate on indices
of bone resorption was small and is consistent with a
previous study in rats with renal ablation.21 Doses of
bisphosphonates that completely suppressed aortic calcifica-
tion did not significantly reduce any index of bone
resorption. Furthermore, there was no consistent correlation
between aortic calcium content and any index of bone
resorption in the entire cohort of uremic rats.
The small increases in parameters of bone resorption
compared with the larger increases in bone formation rate in
the untreated uremic rats do not necessarily indicate a net
increase in bone in this model. Bone resorption cannot be
directly measured and an increase in bone volume was not
observed histologically. Furthermore, this model is super-
imposed on a skeleton that continues to increase during the
life of the rats. This together with the short duration of
the model may explain why bone volume did not decrease
with uremia.
The mechanism by which bisphosphonates reduce bone
resorption and why the effect varies so widely among
different compounds is not completely understood. The fact
that the different potencies in vivo are not always reproduced
in vitro15 suggests that differences in pharmacokinetics may
contribute. Bioavailability can vary due to differences in
binding to proteins, soft tissues, and bone15,23 and the
pharmacokinetics of subcutaneous administration as used in
rats have not been examined. Although the inhibition of
bone resorption has been documented in several conditions
associated with increased bone turnover, there has been only
one previous study of bisphosphonate therapy in uremic
osteodystrophy.21 Weekly treatment with ibandronate in
partially nephrectomized rats did not alter osteoclast
numbers or erosion surface but did reduce erosion depth.
However, as in the present study, there were greater
reductions in bone formation. As formation and resorption
are normally coupled, the decrease in bone formation could
represent a restoration of normal bone turnover. This is
unlikely since, in this study, formation was reduced to levels
well below control (nonuremic) animals. The results of these
two studies suggest that caution must be used in extrapolat-
ing reported potencies of bisphosphonates for bone resorp-
tion and bone formation to bone metabolism in renal failure.
As rat bone lacks the haversian system present in humans, the
results cannot necessarily be extrapolated to patients with
renal failure.
Inhibition of aortic calcification actually correlated better
with inhibition of bone formation, which was almost
completely suppressed by bisphosphonate. The potency of
different bisphosphonates in inhibiting bone formation varies
much less than the potency for inhibiting bone resorp-
tion,15,23 owing to the fact that inhibition of mineralization is
a direct effect on hydroxyapatite formation related to the
pyrophosphate-like backbone15 and not influenced as much
by the side groups.23 The results in uremic rats showing
decreased bone formation and mineralizing surface without a
decrease in osteoblast number is consistent with this
mineralizing defect. The fact that osteoid thickness did not
increase is probably due to the short duration of treatment.
The greater potency of pamidronate compared to etidronate
in vivo may relate to pharmacokinetics since it is less potent
than etidronate on bone in vitro23 and was less effective at
inhibiting calcification of aortas in vitro in the current study.
The frequent (daily) dosing combined with decreased
clearance due to renal failure may also have contributed to
the potency of pamidronate in vivo as continuous presence of
pamidronate versus intermittent exposure greatly increases
inhibition of bone mineralization in vitro.23 The correlation
between aortic calcification and bone formation suggests that
the two are linked, but it is also possible that inhibition of
vascular calcification is a direct effect of bisphosphonates on
hydroxyapatite formation that also occurs in the bone.
The fact that both bisphosphonates also prevented
calcification of rat aortas in culture clearly demonstrates
direct inhibition independent of the bone. Inhibition of the
aortic calcification induced by alkaline phosphatase in vitro is
consistent with the fact that bisphosphonates can substitute
for the pyrophosphate removed by alkaline phosphatase and
are resistant to the action of this enzyme. Bisphosphonates
also inhibited calcification of injured aortas cultured in the
absence of alkaline phosphatase, although higher concentra-
tions were required. The mechanism of the calcification in
injured aortas is not clear but upregulation of alkaline
phosphatase does occur.7 Calcification is usually more robust
in injured aortas, which may require greater quantities of
bisphosphonates as inhibition likely requires binding to the
hydroxyapatite.24 The greater potency of etidronate com-
pared with pamidronate in vitro is consistent with results in
the bone23 and indicates a direct physicochemical action of
bisphosphonates on hydroxyapatite formation. Pamidronate
contains a side group on the carbon atom that imbues it
with an additional, intracellular action that is thought
to be responsible for the greater inhibition of bone
resorption.15 This clearly does not enhance inhibition of
aortic calcification in vitro and appears to interfere with the
physicochemical action.
In addition to preventing de novo calcification in vitro,
bisphosphonates were also effective in arresting progression
of established calcification. This required significantly greater
amounts, which may be related to the extent of calcification.
Bisphosphonates bind avidly to hydroxyapatite24 and this is
probably the mechanism by which calcification is blocked.
Thus the amount required to prevent calcification is probably
dependent on the amount of hydroxyapatite present, which
has been demonstrated in vitro with PPi.5 Although
etidronate blocked further calcification, it did not directly
reverse calcification. The kinetics of calcium release from
calcified vessels revealed two pools. The majority of the
calcium was released very slowly with a half-life of 40–120
days. This undoubtedly represents apatitic calcium, which is
highly insoluble under physiologic conditions.25 The re-
mainder of the calcium was released more rapidly and
probably represents amorphous calcium phosphate or
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brushite, which is far more soluble.26 Although etidronate
did not increase the rate of either pool, reversal of
calcification could occur over an extended period of time
as the calcifications dissolve when further hydroxyapatite
formation is prevented. The lack of effect on dissolution is in
contrast to the previously reported inhibition of hydro-
xyapatite dissolution by bisphosphonates at similar concen-
trations.27 Possible explanations for this difference are that
the previous study used chemically prepared hydroxyapatite,
was not performed in a biological system, and was performed
in the absence of calcium or phosphate. Physiologic
concentrations of calcium and phosphate were used in the
present studies to mimic conditions in vivo and to maintain
the health of the cells. Thus, some or all of the 45Ca release
could represent exchange rather than net release of calcium.
Alkaline phosphatase has a critical role in calcification by
virtue of hydrolyzing PPi.7,28 Although bisphosphonates are
not hydrolyzable, they could interact with the catalytic site
and interfere with PPi hydrolysis, resulting in higher PPi
levels and inhibition of calcification. Such inhibition has been
reported but required millimolar concentrations.20 In the
current studies, pamidronate did not alter the rate of
hydrolysis of PPi by aortas, indicating that this is not a
mechanism for preventing calcification. Another key protein
is matrix Gla protein (MGP), an inhibitor of vascular
calcification.29 Despite a report that bisphosphonates reduce
expression of mRNA for MGP in cultured smooth muscle
cells,19 no changes were detected in cultured aortas. There
was also no change in the amount of mRNA for osteopontin,
another inhibitor.30 The increased abundance of these
mRNAs during culture under calcifying conditions is
consistent with the increased protein expression that is
observed (Lomashvili KA and O’Neill WC, unpublished
studies). Etidronate also did not alter the content of mRNA
for runx2, an osteogenic transcription factor that has been
hypothesized to drive smooth muscle calcification,31 or
osterix, a bone-specific transcription factor. Of note, the
abundance of both mRNAs was very low in aortas and did
not increase under calcifying conditions. These negative data
all point to direct inhibition of hydroxyapatite formation as
the mechanism for bisphosphonate action in cultured aortas.
This study demonstrates that inhibition of uremic vascular
calcification by bisphosphonates correlates more strongly
with inhibition of bone formation than inhibition of bone
resorption. Although it is possible that there is a direct link
between bone formation and vascular calcification, the in
vitro data indicate that bisphosphonates directly inhibit
hydroxyapatite formation at both locations. This suggests
that doses of bisphosphonates necessary to prevent vascular
calcification will also impair bone formation, thus limiting
their therapeutic potential. However, aortic calcification was
prevented at a dose of pamidronate that did not suppress
bone formation below normal levels, indicating that a
therapeutic window may exist. The lowest dose of pami-
dronate used in this study (0.03 mg/kg per day for 28 days) is
similar to the dose in humans to inhibit bone resorption
(90 mg monthly). However, subcutaneous administration
may not be equivalent to intravenous injection in humans
and pamidronate clearance may be significantly retarded by
renal failure. Also, this model of renal failure and vascular
calcification in rats may not be applicable to humans with
renal failure because of the nature of the renal lesion, the
short duration of uremia, and the differences between rat and
human bone. Although it is difficult to compare these doses,
it is likely that the doses, which inhibit vascular calcification
are substantially higher than the antiresorptive doses
currently used in humans. Additional studies with careful
attention to drug bioavailability, dynamics of vascular
calcification, and changes in bone metabolism will be
required to determine whether bisphosphonates are clinically
useful in preventing uremic vascular calcification. Although
this study does not provide evidence for a causal relationship
between bone metabolism and vascular calcification, it does
not refute this putative link. As bisphosphonates have direct
effects on vascular calcification, they cannot be used to
address this hypothesis.
MATERIALS AND METHODS
Animal studies
Chronic renal failure was produced by feeding adenine to rats.32,33
This results in crystallization of 2,8-dihydroxyadenine in the tubules
and interstitium with resulting interstitial nephritis and fibrosis and
all the metabolic abnormalities of chronic renal failure.32 Male
Sprague-Dawley rats were obtained from Charles River Laboratories
and fed a standard rodent diet until body weight exceeded 300 g.
Rats were then fed a 2.5% protein diet (Harlan Teklad, Madison, WI,
USA), which enhances vascular calcification,18 supplemented with
phosphate. This diet contained 1.06% calcium and 0.92%
phosphorus. The adenine content was 0.75% for the first 7 days
and 0.5% thereafter. Control rats were fed the identical diet without
adenine but restricted in amount so that their weight loss matched
that of the adenine-fed rats. Etidronate (Sigma-Aldrich, St Louis,
MO, USA) and pamidronate (Novartis, Basel, Switzerland) were
administered in saline, buffered to pH 7.4, by daily subcutaneous
injection starting on the first day of the adenine diet. The doses of
etidronate were 0.17, 1.7, and 17 mg/kg per day (0.8, 8, and 80 mmol/
kg per day) and the doses of pamidronate were 0.03, 0.3, and 3 mg/
kg per day (0.08, 0.8, and 8 mmol/kg per day). There were seven rats
in each group with renal failure and six pair-fed rats without renal
failure. Rats were killed after 28 days and aortas were perfused with
saline, harvested, and cleaned. After drying and weighing, the aortas
were extracted overnight in 1 M HCl and calcium in the extract was
measured colorimetrically by the cresolphthalein method.34 Plasma
urea was measured colorimetrically by the urease-glutamate
dehydrogenase method (Sigma-Aldrich, St Louis, MO), plasma
phosphate was measured colorimetrically by the molybdate
method,35 and plasma calcium was measured by the cresolpthalein
method.34 Plasma intact parathyroid hormone levels were deter-
mined using a rat enzyme-linked immunoassay (Scantibodies Inc.,
Santee, CA, USA).
Bone histomorphometry
Rats received intraperitoneal injections of calcein (2 mg) on days 20
and 25. At the time of killing, one femur was removed, cleaned of
attached tissue, and placed in absolute ethanol. After dehydration,
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samples were embedded in methyl methacrylate and eight
sections were cut serially at 4 mm thickness with a heavy-duty
microtome. This thickness allows analysis of the same histologic
features in slides prepared for light and fluorescent microscopy.
Every other section was stained with the modified Masson–Goldner
trichrome technique whereas the other sections were reserved for
fluorescence microscopy. Static and dynamic parameters of bone
structure, formation, and resorption were measured at a standar-
dized site below the growth plate using a semi-automatic
method.36,37
Aortic calcification in vitro
Aortas were cultured from adult, male Sprague–Dawley rats as
described earlier.7 Briefly, aortas were dissected from surrounding
tissue and perfused with physiologic saline under sterile conditions.
After the adventitia was carefully removed with scissors to avoid any
mechanical trauma, 2–3 mm rings were placed in high-phosphate
DMEM medium containing 3.75 U/ml of calf intestinal alkaline
phosphatase and incubated at 371C in 5% CO2 with medium
changes every 3 days. In studies comparing potencies of bispho-
sphonates, 25 mM warfarin was added to maximize calcification.
Calcification was also produced by rubbing aortas with a cotton
swab followed by culture without alkaline phosphatase. The total
concentrations of calcium and phosphate were 1.8 and 3.8 mM
respectively. To quantitate calcification, 45Ca was added to the
medium and incorporation into the aortic rings was measured after
extracting the rings in 3 M HCl.
Calcium release
Injured aortas were cultured for 9 days in high-phosphate DMEM
containing 45Ca. The aortas were washed several times in
low-phosphate DMEM and then placed in the same medium
for 4 h to wash out unbound 45Ca. Medium was then changed
and samples were removed at the indicated times for measurement
of 45Ca. After 5 days, 45Ca content of the aortas was measured
as above.
Pyrophosphate hydrolysis
This was measured as described earlier9 by incubating freshly
isolated aortas with 1 mM sodium pyrophosphate and [32P]PPi
(3mCi/ml) and then adding ammonium molybdate (to bind
orthophosphate) followed by extraction with isobutanol/petroleum
ether (4:1) to separate phosphomolybdate from pyrophosphate. The
rings were then dried and weighed.
Quantitative polymerase chain reaction
Aortas were frozen in liquid nitrogen, powdered and then extracted
with a guanidinium and phenol solution on ice with additional
homogenization. Chlorophorm was added and RNA extracted by
centrifugation. cDNA was synthesized using 2 mg of total RNA from
each sample with iScript cDNA Synthesis Kit (Bio-Rad, Hercules,
CA, USA) and quantitative PCR performed with an iCycler iQ
Detection System using iQ SYBR Green Supermix (Bio-Rad). To
avoid amplification of genomic DNA, primers for QPCR were
designed to flanking at least on intron. Sequences of the primer pairs
(F: forward; R: reverse) were as follow. Osteopontin:
CTGTCTCCCGGTGAAAGTG (F), GTCATCCGTTTCTTCAGAGG
(R); matrix gla protein: AGGCAGACTCACAGGACACC (F),
CATTTCTCCGGTTGGTGAAG (R); Runx 2: CTTCACAAATCCTC
CCCAAG (F), GAGGCGGTCAGAGAACAAAC (R); Osterix: TCTC
CATCTGCCTGACTCCT (F), TTCTTTGTGCCTCCTTTTCC (R).
Statistics
The Mann–Whitney U-test was applied to nonparametric data
(aortic calcium content and bone parameters). Differences
between groups for all other data were examined by Student’s
t-test.
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